Literature DB >> 4169685

Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide.

E Kast.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 4169685     DOI： 10.1007/BF01575629

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN： 0033-2720


× No keyword cloud information.
  5 in total

1.  STUDY OF LYSERGIC ACID DIETHYLAMIDE AS AN ANALGESIC AGENT.

Authors:  E C KAST; V J COLLINS
Journal:  Anesth Analg       Date:  1964 May-Jun       Impact factor: 5.108

2.  The measurement of pain: a new approach to an old problem.

Authors:  E C KAST
Journal:  J New Drugs       Date:  1962 Nov-Dec

3.  Pharmacologic advances in psychiatry.

Authors:  S MALITZ
Journal:  N Y State J Med       Date:  1957-10-15

4.  Pharmacotherapeutic evaluation and the psychiatric setting.

Authors:  M SABSHIN; J RAMOT
Journal:  AMA Arch Neurol Psychiatry       Date:  1956-04

5.  [Effect of LSD25 on the phantom limb; the problem of body scheme and the therapeutic use of LSD25 on phantom pain].

Authors:  S KUROMARU; S OKADA; M HANADA; Y KASAHARA; K SAKAMOTO
Journal:  Seishin Shinkeigaku Zasshi       Date:  1962-06-25
  5 in total
  13 in total

Review 1.  Hallucinogens: an update.

Authors:  John H Halpern
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

2.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

Review 3.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

4.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Authors:  Roland R Griffiths; Matthew W Johnson; William A Richards; Brian D Richards; Una McCann; Robert Jesse
Journal:  Psychopharmacology (Berl)       Date:  2011-06-15       Impact factor: 4.530

5.  Iatrogenic anxiety.

Authors:  H H Shey
Journal:  Psychiatr Q       Date:  1971

Review 6.  Potential Therapeutic Effects of Psilocybin.

Authors:  Matthew W Johnson; Roland R Griffiths
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

Review 7.  Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Authors:  Nina Schimmel; Joost J Breeksema; Sanne Y Smith-Apeldoorn; Jolien Veraart; Wim van den Brink; Robert A Schoevers
Journal:  Psychopharmacology (Berl)       Date:  2021-11-23       Impact factor: 4.530

8.  Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness.

Authors:  Yvan Beaussant; James Tulsky; Benjamin Guérin; Claudia Schwarz-Plaschg; Justin J Sanders
Journal:  J Palliat Med       Date:  2021-04-13       Impact factor: 2.947

9.  Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.

Authors:  Stephen Ross; Gabrielle Agin-Liebes; Sharon Lo; Richard J Zeifman; Leila Ghazal; Julia Benville; Silvia Franco Corso; Christian Bjerre Real; Jeffrey Guss; Anthony Bossis; Sarah E Mennenga
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-18

10.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.